Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Launched by BOEHRINGER INGELHEIM · Nov 22, 2023

Keywords

ClinConnect Summary

The Beamion LUNG-2 trial is studying a new medication called zongertinib (BI 1810631) to see if it can help people with advanced non-small cell lung cancer that has a specific type of genetic mutation known as HER2. This study is for adults aged 18 and older who have not yet received any treatment for their cancer, including chemotherapy. The goal is to find out if zongertinib can slow down the progression of cancer more effectively than the current standard treatment, which includes a combination of pembrolizumab (a type of immunotherapy) and chemotherapy.

If you join the trial, you will be randomly assigned to one of two groups: one will receive zongertinib, and the other will receive the standard treatment. You’ll visit the study site every three weeks for check-ups and tests, including scans to monitor your tumor. The study may last up to 70 months, and during this time, doctors will keep track of your health and any side effects you may experience. To participate, you need to have a confirmed diagnosis of advanced non-small cell lung cancer with a HER2 mutation and meet other specific health criteria. This trial offers a chance to access a potentially beneficial treatment while contributing to important research.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Signed and dated written informed consent form (ICF) in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial.
• • 2. Patients ≥18 years of age or over the legal age of consent in countries where that is greater than 18 years at the time of signature of the ICF.
• • 3. Histologically or cytologically confirmed diagnosis of an advanced and/or metastatic non-squamous Non-small cell lung cancer (NSCLC).
• • 4. Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.
• • 5. An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status. If no archival tissue is available, this may be acceptable in exceptional cases after written agreement with the sponsor.
• • 6. Patients who have not received any systemic treatment for unresectable, locally advanced or metastatic disease and are not eligible for curative therapy.
• • 7. Presence of at least one measurable lesion according to Response evaluation criteria in solid tumors (RECIST) 1.1, as determined by the local site investigator/radiology assessment.
• • 8. Eligible to receive treatment with the selected platinum-based doublet-chemotherapy (i.e. cisplatin/pemetrexed or carboplatin/pemetrexed) and pembrolizumab in accordance with the Summaries of Product Characteristics (SmPC)/Product Information.
• • Further inclusion criteria apply.
• Exclusion criteria:
• • 1. Previous or concomitant malignancies other than the one treated in this trial within the last 5 years, except;
• • effectively treated non-melanoma skin cancers
• • effectively treated carcinoma in situ of the cervix
• • effectively treated ductal carcinoma in situ
• • other effectively treated malignancy that is considered cured by local treatment
• • 2. Tumors with targetable alterations with approved available therapy.
• • 3. Lung-specific intercurrent clinically significant severe illness based on investigators assessment.
• • 4. Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
• • 5. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization or planned within 6 months after screening, e.g. hip replacement.
• • 6. Any history of or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the test drug.
• • 7. History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA) classification of ≥ III or IV, unstable angina or poorly controlled arrhythmia which are considered as clinically relevant by the investigator. Myocardial infarction, stroke, or pulmonary embolism within 6 months prior to randomization.
• • 8. Any clinically important abnormalities (as assessed by the investigator) in rhythm, conduction, or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block.
• • Further exclusion criteria apply.